ArticleFrontiers in immunology2026
Integrative omics and experimental validation reveal METTL17 and SLC27A1 as biomarkers and potential therapeutic targets in chronic kidney disease.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) remains a global health challenge characterized by high morbidity and mortality, yet its molecular mechanisms remain incompletely defined. Both mitochondrial dysfunction and macrophage polarization have been implicated in CKD pathogenesis, but the precise gene networks and cellular contexts driving these processes are poorly understood. Methods: An integrative analysis of bulk RNA sequencing, single-cell transcriptomics, and clinical validation was performed to identify key genes linking mitochondrial regulation and macrophage polarization in CKD. Differentially expressed genes were intersected with mitochondria- and macrophage-related gene sets, refined by machine learning, and assessed through functional enrichment, immune infiltration, and network analyses. Single-cell RNA-seq was applied to resolve cellular heterogeneity and ligand-receptor interactions, while experimental validation was carried out in CKD patient peripheral blood samples and a unilateral ureteral obstruction (UUO) mouse model using qPCR, immunohistochemistry, and Western blotting. Results: A total of METTL17 and SLC27A1 were identified as consistently dysregulated genes across datasets, with METTL17 downregulated and SLC27A1 upregulated. Single-cell analysis localized these alterations primarily to proximal tubular cells (PTCs) and smooth muscle cells (SMCs), where ligand-receptor signaling mediated pathogenic intercellular communication. Immune infiltration analysis revealed selective alterations in naïve B cells, activated NK cells, and γδ T cells, highlighting crosstalk between metabolic and immune pathways. Importantly, both genes showed positive correlations with serum creatinine in CKD patients (e.g., SLC27A1: r = 0.467, Conclusion: This study identifies METTL17 and SLC27A1 as key mediators of CKD progression, bridging mitochondrial dysfunction, metabolic reprogramming, and immune imbalance. These findings provide a translational framework for developing biomarker-driven diagnostics and targeted interventions in CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.